Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comments on: Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb-III.

Global & regional health technology assessment·2026
Same author

Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data.

Cancers·2026
Same author

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data.

Oncology research·2026
Same author

Effectiveness of patent foramen ovale occlusion devices versus medical therapy: An indirect comparison based on reconstructed individual patient data.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same author

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Cureus·2026
Same author

Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb-III.

Global & regional health technology assessment·2026

Related Experiment Video

Updated: Jun 28, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Cost effectiveness of sunitinib

Sabrina Trippoli, Andrea Messori

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |November 13, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    Related Experiment Videos

    Last Updated: Jun 28, 2026

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
    13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023